Clinical Trials Logo

Chronic Renal Failure clinical trials

View clinical trials related to Chronic Renal Failure.

Filter by:

NCT ID: NCT00173940 Recruiting - Obesity Clinical Trials

Collection of Blood and Urine Specimens From Volunteers Utilizing Health Examination Services

Start date: n/a
Phase: N/A
Study type: Observational

In summary, the researchers want to construct a longitudinal data bank using voluntary health examination participants. Researchers in the National Taiwan University Hospital (NTUH) campus can utilize these data to clarify the effects of several genetic and environmental factors on various common diseases in Taiwan in the future.

NCT ID: NCT00162487 Recruiting - Clinical trials for Chronic Renal Failure

Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation

Start date: August 2002
Phase: N/A
Study type: Interventional

Several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failure.In conjunction with the decrease in potassium concentration a modest rise in glucose concentration is usually noted. These metabolic effects are characterized by rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting for at least 1 hour. The role played by ß2AR polymorphisms in determining the bronchial and vascular response to ß2AR agonist drugs, have been confirmed by several studies. The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and the metabolic effects of inhaled albuterol.

NCT ID: NCT00161369 Completed - Atherosclerosis Clinical Trials

Effect of Homocysteine and Asymmetric Dimethylarginine on Cardiovascular Events in Hemodialysis Patients

Start date: April 2000
Phase: N/A
Study type: Observational

Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) have recently been recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each of these substances seems to be closely related. This study investigates the association between these substances, and whether elevated serum levels of Hcy and ADMA would be related to a high risk of atherosclerosis and cardiovascular events in maintenance hemodialysis (HD) patients.

NCT ID: NCT00139035 Completed - Clinical trials for Chronic Renal Failure

Effects of Cyclosporine A on Pancreatic Insulin Secretion

Start date: April 2005
Phase: Phase 4
Study type: Interventional

Our primary aim is to investigate if cyclosporine A reduces insulin secretion.

NCT ID: NCT00111995 Completed - Anemia Clinical Trials

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Start date: May 2002
Phase: Phase 4
Study type: Interventional

This study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile.

NCT ID: NCT00109291 Terminated - Anemia Clinical Trials

Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease

Start date: March 2005
Phase: Phase 2
Study type: Interventional

To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.

NCT ID: NCT00097747 Completed - Cancer Clinical Trials

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.

NCT ID: NCT00086164 Terminated - Clinical trials for Chronic Renal Failure

Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis

Start date: May 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed for hemodialysis at 6 months after enrollment.